Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting

ERAS-0015 and ERAS-4001 showed robust anti-tumor activity as monotherapy and combination therapy

First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling

Read more at globenewswire.com